Supriya Lifescience Q1 FY27 Share Price & Earnings Call Analysis
- Market cap
- ₹6,996 Cr
- P/E
- 35.20
- ROE
- 19.06%
- PEG
- 1.07
- Price to sales
- 8.00
- Debt to equity
- 0.00
- 52W high / low
- ₹1,052 / ₹553
- Sales growth (5Y)
- 16.17%
- EBITDA margin
- 33.21%
- Net profit margin
- 25.26%
- Promoter holding
- 68.30%
- Sales (last year)
- ₹873 Cr
Supriya Lifescience is engaged in the manufacturing of Active pharmaceutical ingredients (APIs). As of March 31, 2021, the company produces 38 APIs focused on diverse therapeutic segments such as antihistamine, analgesic, anaesthetic, vitamin, anti-asthmatic and anti-allergic.[1]
Guidance scorecard · Q1 FY27 call
What Supriya Lifescience Ltd's management guided
and where it ranks in Pharmaceuticals & Biotechnology
Pharmaceuticals & Biotechnology
RevenueQ1 FY27 call
20–40%- Supriya Lifescience targets a revenue of Rs. 1,000 crores by FY '27, reflecting strong demand and robust product pipeline.
- The company expects a CAGR growth of about 20% year-on-year beyond FY '27, supported by new products and capacity expansions.
- Q1 FY '27 revenue was Rs. 190 crores, showing 31% YoY growth despite water scarcity issues.
- Growth is anticipated to accelerate in the second half of FY '27 due to scaling-up of liquid anesthetic products, cardiovascular drugs, and launch of contrast media products.
- Continued addition of new products, new therapy verticals, and CMO-CDMO collaborations at API and formulation levels will support sustained growth.
2 more points from Supriya Lifescience Ltd's call on revenue
Create a free account to keep reading this call
MarginsQ1 FY27 call
FlatSee what Supriya Lifescience Ltd said on margins — free account, 30 seconds.
CapexQ1 FY27 call
Planned- Patalganga Facility Investment: Phase-1 CapEx earmarked at around Rs. 200 crores, including two API/advanced intermediate blocks and two formulation blocks. Construction started with boundary walls already underway. API block prioritized initially due to…
- Isambe Project: Initial phase CapEx estimated at Rs. 200 crores with potential for larger investment in subsequent phases.
- Ambernath Facility: Depreciation expected at Rs. 14-15 crores annually; facility recently started contributing to revenue and scheduled for EU audit in November.
2 more points from Supriya Lifescience Ltd's call on capex
Create a free account to keep reading this call
FundraisingQ1 FY27 call
See what Supriya Lifescience Ltd said on fundraising — free account, 30 seconds.
Order bookQ1 FY27 call
Rising- The company is scaling its CDMO-CMO business with promising progress.
- They are very close to signing a term sheet for a large anesthetic CDMO contract, expected to be announced next quarter.
- Qualification work and quality approvals for this contract are largely completed.
- New product launches, including anesthetic liquids and cardiovascular drugs, are expected to contribute to order growth.
- The company anticipates a robust product pipeline supporting sustained demand across various therapeutic segments.
2 more points from Supriya Lifescience Ltd's call on the order book
Create a free account to keep reading this call
Ranges are what management guided for revenue growth and margins on the latest earnings call. Not investment advice, and not a forecast of returns.
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Peers
Pharmaceuticals & Biotechnology companies ranked on guidance
| # | Company | Revenue guided | Margin guided | Market cap | P/E |
|---|---|---|---|---|---|
| 1 | 40%+ | Up 2%+ | ₹556 Cr | 22.1 | |
| 2 | 40%+ | Up 0–2% | ₹215 Cr | 22.2 | |
| 3 | 40%+ | Flat | ₹16,144 Cr | — | |
| 4 | 40%+ | Flat | ₹6,072 Cr | 48.0 | |
| 5 | 40%+ | Flat | ₹40 Cr | — | |
| 6 | 20–40% | Up 2%+ | ₹50,220 Cr | 43.8 |
Sign up free to see every company in the sector ranking and track Supriya Lifescience Ltd.
Pro shows every company guiding 40%+ revenue growth →Full Pharmaceuticals & Biotechnology rankingFinancials of Supriya Lifescience Ltd
Quarterly Results, Profit & Loss, Balance Sheet, Cash Flows, and Ratios are shown below as separate sections.
Financials of Supriya Lifescience Ltd
Quarterly Results
Quarter-by-quarter operating performance
| Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 142 | 132 | 140 | 140 | 158 | 161 | 166 | 186 | 184 | 145 | 200 | 206 | 277 |
| Expenses + | 87 | 88 | 108 | 99 | 103 | 98 | 101 | 120 | 117 | 93 | 127 | 134 | 179 |
| Operating Profit | 55 | 44 | 32 | 41 | 56 | 63 | 65 | 66 | 68 | 52 | 73 | 72 | 98 |
| OPM % | 39% | 34% | 23% | 30% | 35% | 39% | 39% | 36% | 37% | 36% | 36% | 35% | 35% |
| Other Income + | 2 | 3 | 2 | 3 | 2 | 2 | 3 | 2 | 3 | 3 | 3 | 2 | 3 |
| Interest | 1 | 1 | 0 | 0 | 1 | 0 | 0 | 1 | 0 | 1 | 0 | 0 | 0 |
| Depreciation | 3 | 4 | 4 | 4 | 4 | 5 | 5 | 5 | 6 | 6 | 7 | 7 | 8 |
| Profit before tax | 53 | 43 | 30 | 40 | 53 | 60 | 62 | 63 | 64 | 47 | 68 | 67 | 92 |
| Tax % | 28% | 33% | 20% | 26% | 31% | 25% | 26% | 25% | 21% | 27% | 26% | 26% | 19% |
| Net Profit + | 38 | 29 | 24 | 30 | 37 | 45 | 46 | 47 | 50 | 35 | 50 | 50 | 74 |
| EPS in Rs | 4.75 | 3.54 | 2.97 | 3.70 | 4.59 | 5.55 | 5.73 | 5.81 | 6.26 | 4.32 | 6.27 | 6.17 | 9.22 |
Financials of Supriya Lifescience Ltd
Profit & Loss
Annual income statement trend
| Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 184 | 213 | 278 | 312 | 391 | 530 | 461 | 570 | 696 | 828 |
| Expenses + | 166 | 191 | 213 | 213 | 218 | 316 | 332 | 394 | 436 | 534 |
| Operating Profit | 17 | 22 | 65 | 98 | 173 | 214 | 129 | 176 | 261 | 294 |
| OPM % | 9% | 10% | 23% | 32% | 44% | 40% | 28% | 31% | 37% | 36% |
| Other Income + | 7 | 9 | 8 | 11 | 5 | 8 | 9 | 11 | 10 | 11 |
| Interest | 12 | 11 | 10 | 7 | 4 | 4 | 3 | 5 | 2 | 2 |
| Depreciation | 5 | 5 | 5 | 6 | 7 | 10 | 12 | 16 | 20 | 28 |
| Profit before tax | 8 | 14 | 57 | 96 | 167 | 207 | 123 | 166 | 248 | 275 |
| Tax % | 30% | 40% | 31% | 24% | 26% | 27% | 27% | 28% | 24% | 24% |
| Net Profit + | 6 | 9 | 39 | 73 | 124 | 152 | 90 | 119 | 188 | 209 |
| EPS in Rs | 3.87 | 5.96 | 26.93 | 50.11 | 16.89 | 18.86 | 11.17 | 14.80 | 23.35 | 25.98 |
| Dividend Payout % | 0% | 0% | 0% | 20% | 3% | 3% | 5% | 5% | 4% | 4% |
Financials of Supriya Lifescience Ltd
Balance Sheet
Capital structure and asset base
| Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 15 | 15 | 15 | 15 | 15 | 16 | 16 | 16 | 16 | 16 |
| Reserves | 31 | 40 | 79 | 134 | 254 | 600 | 683 | 799 | 981 | 1,182 |
| Borrowings + | 140 | 130 | 90 | 82 | 72 | 27 | 22 | 5 | 5 | 5 |
| Other Liabilities + | 55 | 60 | 69 | 105 | 105 | 92 | 98 | 101 | 110 | 154 |
| Total Liabilities | 241 | 245 | 253 | 336 | 445 | 735 | 820 | 921 | 1,112 | 1,357 |
| Fixed Assets + | 89 | 91 | 85 | 99 | 100 | 190 | 262 | 310 | 453 | 689 |
| CWIP | 36 | 34 | 35 | 40 | 79 | 43 | 68 | 149 | 148 | 36 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 25 | 64 | 63 | 99 |
| Other Assets + | 117 | 120 | 133 | 197 | 267 | 502 | 466 | 399 | 448 | 534 |
| Total Assets | 241 | 245 | 253 | 336 | 445 | 735 | 820 | 921 | 1,112 | 1,357 |
Financials of Supriya Lifescience Ltd
Cash Flows
Operating, investing and financing cash movement
| Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operating Activity + | 27 | 28 | 49 | 117 | 76 | 49 | 64 | 113 | 165 | |
| Cash from Investing Activity + | -27 | -5 | 5 | -25 | -47 | -60 | -124 | -174 | -152 | |
| Cash from Financing Activity + | -2 | -20 | -50 | -29 | -15 | 150 | -10 | -22 | -8 | |
| Net Cash Flow | -2 | 3 | 4 | 62 | 15 | 139 | -70 | -83 | 4 | |
| Free Cash Flow | -0 | 23 | 54 | 92 | 29 | -11 | -44 | -32 | 2 | |
| CFO/OP | 158% | 141% | 97% | 146% | 61% | 51% | 73% | 86% | 86% |
Financials of Supriya Lifescience Ltd
Ratios
Working capital efficiency and return ratios
| Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 99 | 92 | 79 | 60 | 69 | 79 | 67 | 71 | 70 | 97 |
| Inventory Days | 113 | 85 | 77 | 130 | 206 | 172 | 234 | 140 | 205 | 229 |
| Days Payable | 121 | 112 | 110 | 130 | 145 | 91 | 130 | 98 | 129 | 159 |
| Cash Conversion Cycle | 91 | 64 | 45 | 61 | 130 | 160 | 171 | 114 | 146 | 167 |
| Working Capital Days | -69 | -50 | -5 | -40 | 28 | 117 | 168 | 157 | 144 | 147 |
| ROCE % | 14% | 37% | 50% | 60% | 43% | 19% | 22% | 27% | 25% |
Guidance history
How Supriya Lifescience Ltd's guidance has moved, call by call
| Call | Revenue | Margins | Capex | Fundraising | Order book |
|---|---|---|---|---|---|
| Q1 FY27 call → | 20–40% | Flat | Planned | — | Rising |
| Q4 FY26 call → | 20–40% | Flat | Planned | — | Rising |
| Q3 FY26 call → | 20–40% | Flat | Planned | — | — |
| Q2 FY26 call → | 20–40% | Flat | Planned | — | Rising |
What management guided on each call, newest first. Not investment advice, and not a forecast of returns.
Momentum score · price trend
73 out of 100 — Strengthening
Over the past year its share price has done better than most of the stocks we track.
| Period | Share price change | Better than … of 1,910 stocks |
|---|---|---|
| Last 12 months | +16.3% | 71% |
| Last 6 months | +25.1% | 78% |
| Last 3 months | +1.1% | 65% |
How we calculate it
“Better than 30%” means that over that period the share price did better than 30 out of every 100 stocks we track (1,910 Indian companies worth ₹500 Cr or more, with at least a year of prices).
The score weighs the longer periods more: 40% × 12-month + 40% × 6-month + 20% × 3-month. For Supriya Lifescience Ltd: 0.4 × 71 + 0.4 × 78 + 0.2 × 65 = 73.
Strengthening is 70 and above, Steady 40 to 70, Cooling below 40. Scores are recalculated every night after the market closes.
Full methodology →This describes only how the share price has moved up to 29 Oct 2026, compared with other stocks. It says nothing about the business, and it is not a prediction, a price target or a recommendation to buy or sell.
Continue your research
What Supriya Lifescience Ltd's management said in earlier quarters
- Q1 FY27 earnings call analysis →
- Q2 FY26 earnings call analysis →
- Q3 FY26 earnings call analysis →
- Q4 FY26 earnings call analysis →
- Q1 FY26 earnings call →
- Q4 FY25 earnings call →
- Q3 FY25 earnings call →
- Q2 FY25 earnings call →
- Q1 FY25 earnings call →
- Q4 FY24 earnings call →
- Q3 FY24 earnings call →
- Q2 FY24 earnings call →
Others in Pharmaceuticals & Biotechnology this season
- Lincoln Pharmaceuticals Ltd (Q2 FY27)
2,798.12 Lakhs increase (approximately 17.1% growth) . Key results statement takeaways from Lincoln Pharmaceuticals Ltd's Q2 FY27 results statement — and how it
- Alivus Life Sciences Ltd (Q2 FY27)
Q2 FY27 Revenue from Operations: ₹6,820 million, up 16.0% year-on-year (YoY). Key investor presentation takeaways from Alivus Life Sciences Ltd's Q2 FY27 invest
- Strides Pharma Science Ltd (Q2 FY27)
Q2FY27 Revenue: ₹14,297 million, up 17.1% YoY (Page 4, 15) . Key investor presentation takeaways from Strides Pharma Science Ltd's Q2 FY27 investor presentation
- Laurus Labs Ltd (Q2 FY27)
2Q FY27 Revenue:** ₹2,206 crore, up 33% year-on-year (Y-o-Y) and 9% quarter-on-quarter (Q-o-Q). Key investor presentation takeaways from Laurus Labs Ltd's Q2 FY